Clinical Trials Logo

Clinical Trial Summary

A Controlled Human Infection Model (CHIM) is being developed to provide early proof-of-concept that experimental infection with the intestinal nematode, Trichuris trichiura, is feasible and safe. The proposed model consists of enrolling consenting, healthy, trichuriasis-naïve adults and challenging them with the investigational product, Trichuris trichiura Egg Inoculum, to assess their ability to result in detectable infection. The proposed study will be a feasibility study that will consist of administering different doses of the Trichuris trichiura Egg Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of T. trichiura eggs) that is safe, well-tolerated and results in consistent infection.


Clinical Trial Description

Open-label, dose-escalation clinical study in healthy, trichuriasis-naïve adults: Study sites: - George Washington University, Washington, DC - Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD - Number of participants: up to 18 in 3 cohorts of 6 volunteers each In Cohort 1, six (6) volunteers will receive an inoculum of 150 embryonated Trichuris trichiura eggs. In Cohort 2, six (6) volunteers will receive an inoculum of 300 embryonated Trichuris trichiura eggs. In the optional Cohort 3, six (6) volunteers will receive an inoculum of 450 embryonated Trichuris trichiura eggs. The cohorts will be enrolled in a staggered fashion with safety data assessed prior to larval dose escalation. Cohort 2 will be inoculated no earlier than 16 weeks after the last volunteer is inoculated in Cohort 1. The optional Cohort 3 will be inoculated no sooner than 16 weeks after the last volunteer is inoculated in Cohort 2. Cohort 3 will be enrolled only if the tolerability of the experimental infection of Cohort 2 is acceptable and does not result in significant adverse events. - Egg administration schedule: Study Day 0 (single administration) - Route: oral - Doses of T. trichiura Egg Inoculum to be tested: 150, 300 and 450 embryonated eggs (high dose optional) - Study duration: approximately 10 months per study participant ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05706116
Study type Interventional
Source George Washington University
Contact David Diemert, MD
Phone 202-994-2909
Email ddiemert@gwu.edu
Status Not yet recruiting
Phase Phase 1
Start date July 1, 2024
Completion date January 30, 2028

See also
  Status Clinical Trial Phase
Completed NCT03527732 - Efficacy and Safety of IVM/ALB Co-administration Phase 2/Phase 3
Completed NCT06037876 - Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura Phase 3
Completed NCT03527745 - Albendazole Dose Finding and Pharmacokinetics in Children and Adults Phase 2
Not yet recruiting NCT04713787 - A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults Phase 2
Active, not recruiting NCT06188715 - Efficacy and Safety of MOX/ALB Co-administration in SAC Phase 3
Completed NCT04700423 - Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration Phase 2/Phase 3
Recruiting NCT06184399 - Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC Phase 2
Completed NCT00659997 - Efficacy Albendazole and Levamisole Against STH on Unguja Phase 4
Completed NCT04726969 - Efficacy and Safety of MOX/ALB Co-administration Phase 3
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A